{"id":"https://openalex.org/W2767852989","doi":"https://doi.org/10.1002/cpdd.411","title":"In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF\u201000251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor","display_name":"In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF\u201000251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor","publication_year":2017,"publication_date":"2017-11-07","ids":{"openalex":"https://openalex.org/W2767852989","doi":"https://doi.org/10.1002/cpdd.411","mag":"2767852989","pmid":"https://pubmed.ncbi.nlm.nih.gov/29112329","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5900965"},"language":"en","primary_location":{"id":"doi:10.1002/cpdd.411","doi":"https://doi.org/10.1002/cpdd.411","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.411","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.411","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.411","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5020100940","display_name":"Sharon L. Ripp","orcid":"https://orcid.org/0009-0003-1056-8716","observed_orcids":["https://orcid.org/0009-0003-1056-8716"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sharon L. Ripp","raw_affiliation_strings":["Pfizer Inc., Groton, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., Groton, CT, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Arnab Mukherjee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Arnab Mukherjee","raw_affiliation_strings":["Pfizer Inc., Groton, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., Groton, CT, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027421029","display_name":"Heather F. Eng","orcid":"https://orcid.org/0000-0002-2914-3967","observed_orcids":["https://orcid.org/0000-0002-2914-3967"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Heather Eng","raw_affiliation_strings":["Pfizer Inc., Groton, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., Groton, CT, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041090241","display_name":"Thomas C. Stock","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Stock","raw_affiliation_strings":["Pfizer Inc., Collegeville, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., Collegeville, PA, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014612292","display_name":"Dona L. Fleishaker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dona Fleishaker","raw_affiliation_strings":["Pfizer Inc., Groton, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., Groton, CT, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043193284","display_name":"Tina Checchio","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tina Checchio","raw_affiliation_strings":["Pfizer Inc., Groton, CT, USA","Affiliation at the time of the study"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., Groton, CT, USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Affiliation at the time of the study","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5059282099","display_name":"Brinda K. Tammara","orcid":"https://orcid.org/0000-0002-0423-1856","observed_orcids":["https://orcid.org/0000-0002-0423-1856"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brinda Tammara","raw_affiliation_strings":["Pfizer Inc., Collegeville, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., Collegeville, PA, USA","institution_ids":["https://openalex.org/I180857899"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5020100940"],"corresponding_institution_ids":["https://openalex.org/I180857899"],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":{"value":3800,"currency":"USD","value_usd":3800},"fwci":0.0,"has_fulltext":true,"cited_by_count":8,"citation_normalized_percentile":{"value":0.21526139,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"7","issue":"3","first_page":"244","last_page":"255"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glucocorticoid-receptor-agonists","display_name":"glucocorticoid receptor agonists","score":0.8130000233650208},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.7860000133514404},{"id":"https://openalex.org/keywords/cyp3a-inhibition","display_name":"CYP3A inhibition","score":0.8519999980926514},{"id":"https://openalex.org/keywords/cyp3a-induction","display_name":"CYP3A induction","score":0.9480000138282776},{"id":"https://openalex.org/keywords/cyp2d6","display_name":"CYP2D6","score":0.8930000066757202},{"id":"https://openalex.org/keywords/time-dependent-inhibition","display_name":"time-dependent inhibition","score":0.6399999856948853},{"id":"https://openalex.org/keywords/model-based-prediction","display_name":"model-based prediction","score":0.722000002861023},{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":0.7950000166893005},{"id":"https://openalex.org/keywords/prodrugs","display_name":"prodrugs","score":0.4659999907016754}],"concepts":[{"id":"https://openalex.org/C11824378","wikidata":"https://www.wikidata.org/wiki/Q5014970","display_name":"CYP3A","level":4,"score":0.8013208508491516},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.7946938276290894},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7920308709144592},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6761952638626099},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6333956718444824},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5687893629074097},{"id":"https://openalex.org/C59493245","wikidata":"https://www.wikidata.org/wiki/Q14877410","display_name":"Glucocorticoid receptor","level":3,"score":0.5607004165649414},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.5131316781044006},{"id":"https://openalex.org/C2780841215","wikidata":"https://www.wikidata.org/wiki/Q422549","display_name":"Glucocorticoid","level":2,"score":0.5122093558311462},{"id":"https://openalex.org/C2778000748","wikidata":"https://www.wikidata.org/wiki/Q423071","display_name":"Midazolam","level":3,"score":0.5117985606193542},{"id":"https://openalex.org/C109650736","wikidata":"https://www.wikidata.org/wiki/Q424440","display_name":"CYP3A4","level":4,"score":0.49767830967903137},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4976520836353302},{"id":"https://openalex.org/C97320921","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug interaction","level":3,"score":0.4507267475128174},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.31248021125793457},{"id":"https://openalex.org/C526171541","wikidata":"https://www.wikidata.org/wiki/Q407693","display_name":"Cytochrome P450","level":3,"score":0.31006690859794617},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.2681675851345062},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.25450244545936584},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.14530548453330994},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.09703505039215088},{"id":"https://openalex.org/C2776814716","wikidata":"https://www.wikidata.org/wiki/Q574801","display_name":"Sedation","level":2,"score":0.0},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008862","descriptor_name":"Microsomes, Liver","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D008862","descriptor_name":"Microsomes, Liver","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008874","descriptor_name":"Midazolam","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D008874","descriptor_name":"Midazolam","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D010616","descriptor_name":"Phenanthrenes","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D010616","descriptor_name":"Phenanthrenes","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D010616","descriptor_name":"Phenanthrenes","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D010755","descriptor_name":"Organophosphates","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D010755","descriptor_name":"Organophosphates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D010755","descriptor_name":"Organophosphates","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D011355","descriptor_name":"Prodrugs","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D011355","descriptor_name":"Prodrugs","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011355","descriptor_name":"Prodrugs","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D011965","descriptor_name":"Receptors, Glucocorticoid","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D011965","descriptor_name":"Receptors, Glucocorticoid","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D051544","descriptor_name":"Cytochrome P-450 CYP3A","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1002/cpdd.411","doi":"https://doi.org/10.1002/cpdd.411","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.411","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.411","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:4837020","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/pmc/articles/PMC5900965","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:5900965","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5900965","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Pharmacol Drug Dev","raw_type":"Text"},{"id":"pmid:29112329","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29112329","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology in drug development","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1002/cpdd.411","doi":"https://doi.org/10.1002/cpdd.411","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.411","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.411","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320308351","display_name":"American Association of Pharmaceutical Scientists","ror":"https://ror.org/0093x0153"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2767852989.pdf","grobid_xml":"https://content.openalex.org/works/W2767852989.grobid-xml"},"referenced_works_count":23,"referenced_works":["https://openalex.org/W144235401","https://openalex.org/W1526136610","https://openalex.org/W1873795791","https://openalex.org/W1990816446","https://openalex.org/W2010427019","https://openalex.org/W2013096789","https://openalex.org/W2032407781","https://openalex.org/W2056872819","https://openalex.org/W2066756175","https://openalex.org/W2078877556","https://openalex.org/W2083359113","https://openalex.org/W2104296986","https://openalex.org/W2121133349","https://openalex.org/W2139459873","https://openalex.org/W2144815258","https://openalex.org/W2157421942","https://openalex.org/W2164113828","https://openalex.org/W2164383816","https://openalex.org/W2321044345","https://openalex.org/W2381801185","https://openalex.org/W2540742197","https://openalex.org/W2602553973","https://openalex.org/W2765282147"],"related_works":["https://openalex.org/W2540742197","https://openalex.org/W1987956545","https://openalex.org/W2593852767","https://openalex.org/W4283321113","https://openalex.org/W4389152958","https://openalex.org/W2909643805","https://openalex.org/W2090034451","https://openalex.org/W3081999697","https://openalex.org/W1966296289","https://openalex.org/W2318544667"],"abstract_inverted_index":{"Abstract":[0],"The":[1],"dissociated":[2],"agonists":[3],"of":[4,12,27,35,56,76,95,105,115,140,152,190],"the":[5,36,48,110,138,187],"glucocorticoid":[6,37],"receptor":[7],"are":[8,90],"a":[9,23,30,73,102,127],"novel":[10],"class":[11],"agents":[13],"in":[14,60,97,117,147,160,182],"clinical":[15,69,120],"development":[16,189],"for":[17,112,197],"rheumatoid":[18,200],"arthritis.":[19],"PF\u201004171327":[20,141,158,174,193],"(fosdagrocorat)":[21],"is":[22,40,72,100],"phosphate":[24],"ester":[25],"prodrug":[26],"PF\u201000251802":[28,57,71,87,99,191],"(dagrocorat),":[29],"selective":[31],"high\u2010affinity":[32],"partial":[33],"agonist":[34],"receptor,":[38],"which":[39],"further":[41,188],"metabolized":[42],"to":[43,67],"PF\u201004015475.":[44],"This":[45],"study":[46,122,136],"evaluated":[47,137],"cytochrome":[49],"P450":[50],"(CYP)\u2013mediated":[51],"drug\u2013drug":[52],"interaction":[53],"(DDI)":[54],"potential":[55,111,195],"and":[58,62,88,93,145,192],"PF\u201004015475":[59,89],"vitro":[61],"used":[63],"model\u2010based":[64],"prediction":[65,108],"approaches":[66],"estimate":[68],"impact.":[70],"reversible":[74],"inhibitor":[75,104],"several":[77],"CYPs,":[78],"but":[79],"modeling":[80],"has":[81],"suggested":[82,109],"no":[83,176],"clinically":[84],"relevant":[85],"interaction.":[86],"time\u2010dependent":[91,103],"inhibitors":[92],"inducers":[94],"CYP3A":[96,116,129,180],"vitro;":[98],"also":[101],"CYP2D6.":[106],"Model\u2010based":[107],"weak":[113],"inhibition":[114],"vivo.":[118,183],"A":[119,131],"DDI":[121],"was":[123],"conducted":[124],"with":[125,157,199],"midazolam,":[126],"sensitive":[128],"substrate.":[130],"phase":[132],"1":[133],"open\u2010label,":[134],"multiple\u2010dose":[135],"effect":[139,178],"on":[142,179],"midazolam":[143,153],"pharmacokinetics":[144],"safety":[146],"12":[148],"healthy":[149],"volunteers.":[150],"Administration":[151],"alone":[154],"or":[155],"concomitantly":[156],"resulted":[159],"equivalent":[161],"pharmacokinetic":[162],"profiles":[163],"(AUC":[164],"inf":[165],",":[166],"21.17":[167],"vs":[168],"20.28":[169],"ng\u00b7h/mL,":[170],"respectively),":[171],"indicating":[172],"that":[173],"had":[175],"net":[177],"activity":[181],"These":[184],"findings":[185],"support":[186],"as":[194],"treatments":[196],"patients":[198],"arthritis":[201],"(NCT00987038).":[202]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2021,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2017-11-17T00:00:00"}